{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T19:39:49Z","timestamp":1776454789705,"version":"3.51.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA053232"],"award-info":[{"award-number":["R01DA053232"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The COVID-19 pandemic disrupted traditional substance use disorder (SUD) treatment modalities, prompting innovative telemedicine solutions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association between state-level telemedicine policies and SUD treatment during the COVID-19 pandemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>An augmented synthetic control analysis comparing changes in SUD treatment before and after the implementation of telemedicine policies in states that adopted these policies to changes in SUD treatment in comparison states without these policies from 2018 to 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>This study utilized a comprehensive policy database merged with de-identified patient claims data from the OptumLabs\u00ae Data Warehouse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Individuals aged 18 in only fully insured commercial, private plans subject to state insurance policies between January 2018 and December 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Combined implementation of three state telemedicine policies during the early months of the COVID-19 pandemic (March\u2013July 2020), including telemedicine coverage parity, telemedicine payment parity, and in-person relationship waivers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes<\/jats:title>\n                    <jats:p>SUD treatment initiation and continuation, measured at the patient-month level and aggregated to the state-month level for analyses, with subgroup analyses for opioid use disorder (OUD) and alcohol use disorder (AUD) treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Implementation of the three policies was associated with average effects of less than 0.006 percentage points in the proportion of adults initiating SUD, AUD, or OUD treatment between March\/April 2020 and December 2022, with confidence intervals not exceeding a 0.02 percentage point increase or decrease (\n                      <jats:italic>p\u2009<\/jats:italic>\n                      &gt;\u20090.05). Among adults receiving treatment prior to the COVID-19 pandemic, these policies were associated with an estimated average change of less than 1.5 percentage points in the proportion of adults receiving SUD, AUD, or OUD treatment, with confidence intervals not exceeding a 4.5 percentage point increase or decrease (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Our study did not identify impacts of state telemedicine coverage parity, payment parity, and in-person relationship waiver policies on SUD treatment during the COVID-19 pandemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s11606-026-10394-7","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T18:46:49Z","timestamp":1776451609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of State Telemedicine Policies on Substance Use Disorder Treatment During the COVID-19 Pandemic"],"prefix":"10.1007","author":[{"given":"Matthew D.","family":"Eisenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla N.","family":"Tormohlen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander D.","family":"McCourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiani","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghavee","family":"Neupane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fingerhood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Seewald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma Elizabeth","family":"McGinty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"Suppl 1","key":"10394_CR1","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/1468-0009.12602","volume":"101","author":"M Cerd\u00e1","year":"2023","unstructured":"Cerd\u00e1 M, Krawczyk N, Keyes K. The future of the United States overdose crisis: challenges and opportunities. Milbank Q. 2023;101(Suppl 1):478.","journal-title":"Milbank Q."},{"key":"10394_CR2","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators n the United States: Results from the 2022 National Survey on Drug Use and Health (HHS Publication No. PEP23-07-01-006, NSDUH Series H-58). Cent Behav Health Stat Q. 2023. https:\/\/www.samhsa.gov\/data\/report\/2022-nsduh-annual-national-report. Accessed 15 Apr 2024."},{"key":"10394_CR3","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1007\/s11606-020-06299-8","volume":"36","author":"M Shakir","year":"2021","unstructured":"Shakir M, Wakeman S. Substance use disorder and telemedicine: opportunity and concern for the future. J Gen Int Med. 2021;36:2823-2824.","journal-title":"J Gen Int Med."},{"issue":"12","key":"10394_CR4","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1377\/hlthaff.2018.05134","volume":"37","author":"HA Huskamp","year":"2018","unstructured":"Huskamp HA, Busch AB, Souza J, et al. How is telemedicine being used in opioid and other substance use disorder treatment? Health Aff. 2018;37(12):1940-1947.","journal-title":"Health Aff."},{"key":"10394_CR5","doi-asserted-by":"publisher","first-page":"104371","DOI":"10.1016\/j.drugpo.2024.104371","volume":"126","author":"KE Schneider","year":"2024","unstructured":"Schneider KE, Martin EM, Allen ST, et al. Volatile drug use and overdose during the first year of the COVID-19 pandemic in the United States. Int J Drug Policy. 2024;126:104371.","journal-title":"Int J Drug Policy."},{"key":"10394_CR6","doi-asserted-by":"publisher","first-page":"109150","DOI":"10.1016\/j.drugalcdep.2021.109150","volume":"229","author":"A Roberts","year":"2021","unstructured":"Roberts A, Rogers J, Mason R, et al. Alcohol and other substance use during the COVID-19 pandemic: A systematic review. Drug Alcohol Depend. 2021;229:109150.","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10394_CR7","doi-asserted-by":"publisher","first-page":"e231018","DOI":"10.1001\/jamahealthforum.2023.1018","volume":"4","author":"VA Palzes","year":"2023","unstructured":"Palzes VA, Chi FW, Metz VE, et al. Overall and telehealth addiction treatment utilization by age, race, ethnicity, and socioeconomic status in California after COVID-19 policy changes. JAMA Health Forum. 2023;4(5):e231018-e231018.","journal-title":"JAMA Health Forum."},{"issue":"1","key":"10394_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1176\/appi.ps.20230102","volume":"75","author":"KN Tormohlen","year":"2024","unstructured":"Tormohlen KN, Eisenberg MD, Fingerhood MI, et al. Trends in opioid use disorder outpatient treatment and telehealth utilization before and during the COVID-19 pandemic. Psychiatr Serv. 2024;75(1):72-75.","journal-title":"Psychiatr Serv."},{"key":"10394_CR9","doi-asserted-by":"crossref","unstructured":"Ge Y, Eisenberg MD, McGinty EE, Yu J, Tormohlen KN. Examining the use of telehealth to initiate buprenorphine for opioid use disorder treatment. Health Aff Sch. 2024;2(11):qxae137.","DOI":"10.1093\/haschl\/qxae137"},{"issue":"4","key":"10394_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1176\/appi.ps.202100191","volume":"73","author":"J Cantor","year":"2022","unstructured":"Cantor J, McBain RK, Kofner A, Hanson R, Stein BD, Yu H. Telehealth adoption by mental health and substance use disorder treatment facilities in the COVID-19 pandemic. Psychiatr Serv. 2022;73(4):411-417.","journal-title":"Psychiatr Serv."},{"key":"10394_CR11","doi-asserted-by":"crossref","unstructured":"Huskamp HA, Uscher-Pines L, Raja P, Normand S-LT, Mehrotra A, Busch AB. Telemedicine for Initiation of Alcohol Use Disorder Medications. JAMA Netw Open. 2024;7(9):e2431594-e2431594.","DOI":"10.1001\/jamanetworkopen.2024.31594"},{"key":"10394_CR12","doi-asserted-by":"crossref","unstructured":"Huskamp HA, Busch AB, Uscher-Pines L, Barnett ML, Riedel L, Mehrotra A. Treatment of opioid use disorder among commercially insured patients in the context of the COVID-19 pandemic. JAMA: J Am Med Assoc. 2020;324(23):2440\u20132442.","DOI":"10.1001\/jama.2020.21512"},{"key":"10394_CR13","unstructured":"Center for Connected Health Policy (CCHP). State Telehealth Laws & Medicaid Program Policies. 2025. https:\/\/www.cchpca.org\/all-telehealth-policies\/. Accessed 14 Mar 2025."},{"key":"10394_CR14","unstructured":"Pham H, Lin C, Zhu Y, et al. Telemedicine-delivered treatment for substance use disorder: A scoping review. J Telemed Telecare. 2023:1357633X231190945."},{"issue":"1","key":"10394_CR15","doi-asserted-by":"publisher","first-page":"e2252381","DOI":"10.1001\/jamanetworkopen.2022.52381","volume":"6","author":"R Hailu","year":"2023","unstructured":"Hailu R, Mehrotra A, Huskamp HA, Busch AB, Barnett ML. Telemedicine use and quality of opioid use disorder treatment in the US during the COVID-19 pandemic. JAMA Netw Open. 2023;6(1):e2252381-e2252381.","journal-title":"JAMA Netw Open."},{"issue":"10","key":"10394_CR16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamapsychiatry.2022.2284","volume":"79","author":"CM Jones","year":"2022","unstructured":"Jones CM, Shoff C, Hodges K, et al. Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among Medicare beneficiaries before and during the COVID-19 pandemic. JAMA Psychiatr. 2022;79(10):981-992.","journal-title":"JAMA Psychiatr."},{"issue":"10","key":"10394_CR17","doi-asserted-by":"publisher","first-page":"e2336914","DOI":"10.1001\/jamanetworkopen.2023.36914","volume":"6","author":"LR Hammerslag","year":"2023","unstructured":"Hammerslag LR, Mack A, Chandler RK, et al. Telemedicine buprenorphine initiation and retention in opioid use disorder treatment for medicaid enrollees. JAMA Netw Open. 2023;6(10):e2336914-e2336914.","journal-title":"JAMA Netw Open."},{"key":"10394_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13722-015-0035-4","volume":"10","author":"T Molfenter","year":"2015","unstructured":"Molfenter T, Boyle M, Holloway D, Zwick J. Trends in telemedicine use in addiction treatment. Addict Sci Clin Pract. 2015;10:1-9.","journal-title":"Addict Sci Clin Pract."},{"issue":"1","key":"10394_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12911-024-02718-6","volume":"24","author":"Z Papalamprakopoulou","year":"2024","unstructured":"Papalamprakopoulou Z, Ntagianta E, Triantafyllou V, et al. Telehealth to increase healthcare access; perspectives of people who use drugs. BMC Med Inform Decis Making. 2024;24(1):1-10.","journal-title":"BMC Med Inform Decis Making."},{"issue":"5","key":"10394_CR20","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1176\/appi.ps.202100088","volume":"73","author":"TL Mark","year":"2022","unstructured":"Mark TL, Treiman K, Padwa H, Henretty K, Tzeng J, Gilbert M. Addiction treatment and telehealth: review of efficacy and provider insights during the COVID-19 pandemic. Psychiatr Serv. 2022;73(5):484-491.","journal-title":"Psychiatr Serv."},{"issue":"4","key":"10394_CR21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/jrh.12737","volume":"39","author":"D Button","year":"2023","unstructured":"Button D, Levander XA, Cook RR, et al. Substance use disorder treatment and technology access among people who use drugs in rural areas of the United States: A cross\u2010sectional survey. J Rural Health. 2023;39(4):772-779.","journal-title":"J Rural Health."},{"issue":"4","key":"10394_CR22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/jrh.12534","volume":"37","author":"J Chen","year":"2021","unstructured":"Chen J, Amaize A, Barath D. Evaluating telehealth adoption and related barriers among hospitals located in rural and urban areas. J Rural Health. 2021;37(4):801-811.","journal-title":"J Rural Health."},{"issue":"5","key":"10394_CR23","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1176\/appi.ps.202000565","volume":"73","author":"J McNeely","year":"2022","unstructured":"McNeely J, Schatz D, Olfson M, Appleton N, Williams AR. How physician workforce shortages are hampering the response to the opioid crisis. Psychiatr Serv. 2022;73(5):547-554.","journal-title":"Psychiatr Serv."},{"key":"10394_CR24","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1097\/PHH.0000000000001133","volume":"26","author":"S Burris","year":"2020","unstructured":"Burris S, Cloud LK, Penn M. The growing field of legal epidemiology. J Public Health Manag Pract. 2020;26:S4-S9.","journal-title":"J Public Health Manag Pract."},{"issue":"1","key":"10394_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1146\/annurev-publhealth-032315-021841","volume":"37","author":"S Burris","year":"2016","unstructured":"Burris S, Ashe M, Levin D, Penn M, Larkin M. A transdisciplinary approach to public health law: the emerging practice of legal epidemiology. Ann Rev of Publ Health. 2016;37(1):135-148.","journal-title":"Ann Rev of Publ Health."},{"key":"10394_CR26","unstructured":"Augenstein J, Smith AM. Manatt telehealth policy tracker: tracking ongoing federal and state policy changes. 2024. https:\/\/www.manatt.com\/insights\/white-papers\/2025\/manatt-telehealth-policy-tracker-tracking-ongoing-federal-and-state-telehealth-policy-changes. Accessed 14 Mar 2025."},{"issue":"4","key":"10394_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.pop.2022.04.002","volume":"49","author":"J Shaver","year":"2022","unstructured":"Shaver J. The State of Telehealth Before and After the COVID-19 Pandemic. Prim Care. 2022;49(4):517-530.","journal-title":"Prim Care."},{"issue":"536","key":"10394_CR28","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1080\/01621459.2021.1929245","volume":"116","author":"E Ben-Michael","year":"2021","unstructured":"Ben-Michael E, Feller A, Rothstein J. The Augmented Synthetic Control Method. J Am Statl Assoc. 2021;116(536):1789-1803.","journal-title":"J Am Statl Assoc."},{"key":"10394_CR29","doi-asserted-by":"publisher","unstructured":"Tay Wee Teck J, Butner JL, Baldacchino A. Understanding the use of telemedicine across different opioid use disorder treatment models: A scoping review. J Telemed Telecare. 2025;31(4):500\u2013514. https:\/\/doi.org\/10.1177\/1357633X231195607","DOI":"10.1177\/1357633X231195607"},{"key":"10394_CR30","unstructured":"U.S. Department of Health & Human Services. Private insurance coverage for telehealth. 2025. https:\/\/telehealthhhs.gov\/providers\/billing-and-reimbursement\/private-insurance-coverage-for-telehealth#:~:text=Many%20commercial%20health%20plans%20have%20broadened%20coverage,at%20least%20some%20form%20of%20telehealth%20service. Accessed 14 Mar 2025."},{"issue":"12","key":"10394_CR31","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1377\/hlthaff.2018.05101","volume":"37","author":"J Park","year":"2018","unstructured":"Park J, Erikson C, Han X, Iyer P. Are state telehealth policies associated with the use of telehealth services among underserved populations? Health Affairs. 2018;37(12):2060-2068.","journal-title":"Health Affairs."},{"issue":"2","key":"10394_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1377\/hlthaff.2013.1054","volume":"33","author":"J Adler-Milstein","year":"2014","unstructured":"Adler-Milstein J, Kvedar J, Bates DW. Telehealth among US hospitals: several factors, including state reimbursement and licensure policies, influence adoption. Health Aff. 2014;33(2):207-215.","journal-title":"Health Aff."},{"key":"10394_CR33","doi-asserted-by":"crossref","unstructured":"Barnett ML, Ray KN, Souza J, Mehrotra A. Trends in telemedicine use in a large commercially insured population, 2005\u20132017. JAMA: J Am Med Assoc. 2018;320(20):2147\u20132149.","DOI":"10.1001\/jama.2018.12354"},{"issue":"3","key":"10394_CR34","doi-asserted-by":"publisher","first-page":"e212618","DOI":"10.1001\/jamanetworkopen.2021.2618","volume":"4","author":"JP Weiner","year":"2021","unstructured":"Weiner JP, Bandeian S, Hatef E, Lans D, Liu A, Lemke KW. In-person and telehealth ambulatory contacts and costs in a large US insured cohort before and during the COVID-19 pandemic. JAMA Netw Open. 2021;4(3):e212618-e212618.","journal-title":"JAMA Netw Open."},{"issue":"10","key":"10394_CR35","doi-asserted-by":"publisher","first-page":"e2022302","DOI":"10.1001\/jamanetworkopen.2020.22302","volume":"3","author":"SH Fischer","year":"2020","unstructured":"Fischer SH, Ray KN, Mehrotra A, Bloom EL, Uscher-Pines L. Prevalence and characteristics of telehealth utilization in the United States. JAMA Netw Open. 2020;3(10):e2022302-e2022302.","journal-title":"JAMA Netw Open."},{"key":"10394_CR36","first-page":"1","volume":"205","author":"JW Lucas","year":"2024","unstructured":"Lucas JW, Wang X. Declines in Telemedicine Use Among Adults: United States, 2021 and 2022. Natl Health Stat Report. 2024(205):1-11.","journal-title":"Natl Health Stat Report."},{"issue":"5","key":"10394_CR37","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/1475-6773.13666","volume":"56","author":"B Zeldow","year":"2021","unstructured":"Zeldow B, Hatfield LA. Confounding and regression adjustment in difference-in-differences studies. Health Serv Res. 2021;56(5):932-941.","journal-title":"Health Serv Res."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10394-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10394-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10394-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T18:46:54Z","timestamp":1776451614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-026-10394-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":37,"alternative-id":["10394"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10394-7","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Dr Eisenberg received grants from the National Institute on Drug Abuse (NIDA) to support the present study; received grants outside the submitted work from NIDA, NINR, NICHD, and the Commonwealth Fund. Dr McGinty received grants from the National Institute on Drug Abuse (NIDA) to support the present study; received grants outside the submitted work from the National Institute on Mental Health, Commonwealth Fund, NIDA, the Centers for Disease Control and Prevention, and the Novartis Foundation; and received consulting fees from Washington University in St Louis Implementation Research Institute, the Agency for Healthcare Research and Quality Integration Academy, and the Center for Dissemination and Implementation Research at Stanford outside the submitted work. Dr Seewald received salary support from Merck outside the submitted work paid directly to his institution. Dr. Stuart received grants outside the submitted work from NIMH, PCORI, NIDA, NICHD, and NINR, and grant funding and personal consulting fees from Eli Lilly and Company. Dr. Fingerhood received salary support as a co-investigator on grants outside the submitted work from NIDA.\u00a0Dr. McCourt received salary support as a co-investigator on grants outside the submitted work from NIDA, CDC, the Commonwealth Fund, the Joyce Foundation, Arnold Ventures, and RWJF and received unrelated consulting fees from RAND Corp.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}